- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02814058
Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation
Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase I study of zolpidem hemitartarate orodispersible tablet 1.75 mg in fasting and postprandial administration. Sample size is 28 healthy volunteers, male and female, aged from 18 to 50 years old.
This is an open-label, randomized, crossover study. Each volunteer will be randomized to one of the following sequencies:
Sequency 1: zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2) Sequency 2: zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2) Formulation will be administered in a single dose, orally in each period. Trial volunteers will be admitted in two different periods of 36 hours each, when investigational product will be administered and blood samples will be collected at pre-determined periods of time up to 24 hours for pharmacokinetics evaluation.
Primary objective is to evaluate the pharmacokinetics of the new formulation of zolpidem hemitartarate orodispersible tablet 1.75 mg in healthy volunteers. As a secondary objective, it will be evaluated if there is any pharmacokinetics difference between genders.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
SP
-
Bragança Paulista, SP, Brazil, 12916-900
- UNIFAG - Unidade Integrada de Farmacologia e Gastroenterologia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female volunteers, aged from 18 to 50 years old (women cannot be pregnant or in breastfeeding period and should be committed to use an effective contraceptive method during the study)
- Body mass index (BMI) greater than or equal to 18.5 and less than or equal to 29.9 kg/m2
- Good health conditions and without significant diseases, according to best medical judgment, according to medical history, blood pressure and heart rate measurements, pulse, temperature, physical examination, electrocardiogram (ECG) and complementary laboratory tests
- Ability to understand the nature and objectives of the trial, including risks and adverse events, willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by informed consent form signature.
Exclusion Criteria:
- Known hypersensitivity to the investigational product (Zolpidem) or chemically related compounds
- History or presence of hepatic or gastrointestinal diseases, or other condition that interferes with drug absorption, distribution, excretion or metabolism
- Maintenance therapy with any drugs, except oral contraceptives
- History of hepatic, kidney, lungs, gastrointestinal, epileptic, hematologic, psychiatric, cardiologic or allergic diseases of any etiology , that requires pharmacological treatment or considered as clinically relevant by the investigator
- Electrocardiographic findings that at investigator discretion are not recommended for study participation
- Deviations on screening laboratory results that are considered clinically relevant by the investigator
- Smoking
- Intake of more than five cups of coffee or tea per day
- History of abusive use of drugs and alcohol
- Use of regular medication two weeks prior to study enrollment or use of any medications one week prior to study enrollment
- Hospitalization for any reason up to 8 weeks prior to start of first period of trial treatment
- Treatment within 3 months prior to the start of trial treatment, with any drug with known and well-established toxic potential to major organs
- Participation in any pharmacokinetics trial with more than 300 mL of blood draw or administration of any experimental drug within 12 months prior to trial treatment start
- Donation or loss of 450 mL or more of blood within 3 months prior to trial enrollment or donation of more than 1500 mL of blood within 12 months prior to the trial treatment start
- Positive result for the BHCG urine test, performed by female volunteers
- Positive results for the detection of abusive drugs at urine exam
- Result higher than 0.1 mg/L for the etilometer exam
- Any condition, according to investigator's best judgment, that prevents the subject to participate in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequency 1
zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
|
zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
|
Experimental: Sequency 2
zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
|
zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Elimination rate constant (Ke)
Time Frame: 24 hours
|
24 hours
|
Maximum serum concentration (Cmax)
Time Frame: 24 hours
|
24 hours
|
Time to reach maximum (peak) plasma concentration following drug administration (tmax)
Time Frame: 24 hours
|
24 hours
|
Area under the curve (0-last)
Time Frame: 24 hours
|
24 hours
|
Area under the curve (0-inf)
Time Frame: 24 hours
|
24 hours
|
Half life (t1/2)
Time Frame: 24 hours
|
24 hours
|
Volume of distribution (Vd)
Time Frame: 24 hours
|
24 hours
|
Clearance (C)
Time Frame: 24 hours
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events
Time Frame: 60 days
|
60 days
|
Intensity of adverse events
Time Frame: 60 days
|
60 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: José Pedrazzoli Júnior, PhD, UNIFAG - Unidade Integrada de Farmacologia e Gastroenterologia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JPJ15/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on zolpidem hemitartarate 1.75 mg - Sequency 1
-
Biolab Sanus FarmaceuticaCompleted
-
Eisai Co., Ltd.Completed
-
Idorsia Pharmaceuticals Ltd.CompletedInsomnia DisorderUnited States, Germany, Spain, Hungary, Israel, Sweden
-
Daniel BenjaminEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHeart Failure | Epilepsy | Pain | Pneumonia | Sepsis | Inflammation | Hypertension | Chronic Kidney Diseases | Hemophilia | Schizophrenia | Central Nervous System Infections | Nosocomial Pneumonia | Insomnia | Anxiety | Bipolar Disorder | Neutropenia | Staphylococcal Infections | Bradycardia | Seizures | Urinary Tract Infections | Pulmonary... and other conditionsUnited States, Canada, United Kingdom, Israel, Singapore